Surovatamig

Phase 3Small molecule

AstraZeneca

Surovatamig is one of 80 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisRecruiting

Primary Membranous NephropathyRecruiting

Untreated Follicular LymphomaRecruiting

B-Cell Non Hodgkin LymphomaRecruiting

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVRecruiting

Follicular LymphomaActive, not recruiting

Rheumatoid ArthritisPhase 1

Recruiting

Primary Membranous NephropathyPhase 2

Recruiting

Untreated Follicular LymphomaPhase 3

Recruiting

B-Cell Non Hodgkin LymphomaPhase 2

Recruiting

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVPhase 3

Recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Surovatamig

AstraZeneca

Phase 3

1 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Simponi

Johnson & Johnson

Preclinical

19 4

Arcoxia

Novartis

Preclinical

4 5

Ilaris

Novartis

Preclinical

3 6

Actos

Takeda

Preclinical

2 7

Celexa

AbbVie

Preclinical

1 8

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 9

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 10

Cataflam

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Rheumatoid Arthritis

NCT07201558

Q4 2029

Phase 2Recruiting

Primary Membranous Nephropathy

NCT07571746

Q4 2031

Phase 3Recruiting

Untreated Follicular Lymphoma

NCT06549595

Q2 2032

Phase 3Recruiting

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

NCT07509151

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV1 trial

A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07509151·420 enrolled

Rheumatoid Arthritis1 trial

An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT07201558·48 enrolled

Primary Membranous Nephropathy1 trial

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults With Antibody-mediated Kidney Disease

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07571746·43 enrolled

B-cell Non Hodgkin Lymphoma1 trial

A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT06526793·270 enrolled

Untreated Follicular Lymphoma1 trial

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06549595·1,018 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Surovatamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Surovatamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Surovatamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Surovatamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2029

Q4 2031

Q2 2032

Trials by Indication[1]

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV1 trial

Rheumatoid Arthritis1 trial

Primary Membranous Nephropathy1 trial

B-cell Non Hodgkin Lymphoma1 trial

Untreated Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News